Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis
Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis
复制标题
DOI：
10.1136/jnnp.2005.086116
复制
发表时间：
2006-08-01
影响因子：
11
通讯作者：
Gallo, P.
中科院分区：
文献类型：
--
作者：
Perini, P.;Ranzato, F.;Gallo, P.
多发性硬化症患者在临床发病时鞘内免疫球蛋白M的合成被发现与15年后达到的残疾程度(通过扩展残疾状况量表进行评估)相关(p<；0.001)。此外，免疫球蛋白M指数的值与首次复发的时间(p<；0.001)和疾病进展期的开始(p=0.10)之间存在显著的负相关。脑脊液中IgM的预后价值在以前的报道和我们的研究中都得到了证实。如果这些发现在更大范围的多发性硬化症患者中得到证实，神经科医生将获得一个有用的生物学标记，用于选择患者进行免疫调节治疗。
The intrathecal synthesis of IgM, determined at clinical onset in patients with multiple sclerosis, was found to correlate with the degree of disability (as evaluated by means of the Expanded Disability Status Scale) reached 15 years later (p < 0.001). Moreover, a significant inverse correlation was observed between the value of the IgM index and time to the first relapse (p < 0.001) and the initiation of the progressive phase of the disease (p = 0.01). The prognostic value of IgM in the CSF is confirmed in previous reports as well as by our study. If these findings are confirmed in patients with multiple sclerosis in a larger series, a helpful biological marker for selecting patients for immunomodulatory treatments will be available to neurologists.